← Leaderboards
Harshini Neelakantan
Ridgeline Therapeutics, Llc
$5,955,890
Attributed
$6,117,106
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,117,106 · 4
By mechanism
U44$4,202,826 · 1
R44$1,339,717 · 1
R43$322,432 · 1
R41$252,131 · 1
Top collaborators
- Andrea Leah Wiley1 shared
Most similar at Ridgeline Therapeutics, Llc
Same institution · by research overlap
- Stanley Watowich$657,602
- Andrea Leah Wiley$161,216
Others in their field
Other Emerging Leaders on “Muscle Strength”
- James Dale Berry · Brigham And Women'S Hospital$6,045,501
- Ian R Lanza · Mayo Clinic Rochester$3,282,415
- Anthony D Saleh · Mirecule, Inc.$3,123,687
- Carolyn Glass · Duke University$3,115,222
- Andrew Donald Ray · Roswell Park Cancer Institute Corp$3,008,512
- Patricio Sepulveda · Amplo Biotechnology, Inc.$2,999,358
Research focus
Muscle StrengthMuscleDoseNovel TherapeuticsPharmaceutical PreparationsAgedPre-ClinicalOralInjuryAdultClinical TrialsMuscle FunctionOlder PatientRecoverySafetyPreclinical DevelopmentGrowthQuality Of LifeNicotinamide N-MethyltransferaseIn VivoMuscle Satellite CellMuscular AtrophyInvestigational DrugsElderly
Grant awards (8)
Preclinical validation of a novel adjunct small molecule drug to prevent muscle loss and enhance weight loss in older adults$1,339,717
R44 · FY2025 · AG · contact PI
Preclinical Development of a Novel Therapeutic to Rejuvenate Aging Muscle Stem Cells and Enhance Muscle Strength and Function Post Hip Fracture$236,538
U44 · FY2024 · AG · contact PI
Preclinical Development of a Novel Therapeutic to Rejuvenate Aging Muscle Stem Cells and Enhance Muscle Strength and Function Post Hip Fracture$1,242,959
U44 · FY2023 · AG · contact PI
A Novel Small Molecule Oral Therapeutic to Prevent and Reverse Skeletal Muscle Atrophy in Aging Adults$322,432
R43 · FY2023 · AG
Preclinical Development of a Novel Therapeutic to Rejuvenate Aging Muscle Stem Cells and Enhance Muscle Strength and Function Post Hip Fracture$247,436
U44 · FY2023 · AG · contact PI
Preclinical Development of a Novel Therapeutic to Rejuvenate Aging Muscle Stem Cells and Enhance Muscle Strength and Function Post Hip Fracture$1,246,866
U44 · FY2022 · AG · contact PI
Preclinical Development of a Novel Therapeutic to Rejuvenate Aging Muscle Stem Cells and Enhance Muscle Strength and Function Post Hip Fracture$1,229,027
U44 · FY2021 · AG · contact PI
Preclinical studies to validate the efficacy of novel mechanism-of-action small molecule inhibitors to treat Duchenne muscular dystrophy$252,131
R41 · FY2019 · AR · contact PI